| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Renal Division (X.W., J.H.), Department of Medicine, Emory University, Atlanta, Georgia 30322; and Nephrology Division (Z.H., J.D., W.E.M.), Baylor College of Medicine, Houston, Texas 77030
Address all correspondence and requests for reprints to: Xiaonan Wang, M.D., Renal Division, WMB 338, Emory University School of Medicine, M/S 1930/001/1AG, 1639 Pierce Drive, Atlanta, Georgia 30322. E-mail: xwang03{at}emory.edu.
Conditions such as acidosis, uremia, and sepsis are characterized by insulin resistance and muscle wasting, but whether the insulin resistance associated with these disorders contributes to muscle atrophy is unclear. We examined this question in db/db mice with increased blood glucose despite high levels of plasma insulin. Compared with control littermate mice, the weights of different muscles in db/db mice and the cross-sectional areas of muscles were smaller. In muscle of db/db mice, protein degradation and activities of the major proteolytic systems, caspase-3 and the proteasome, were increased. We examined signals that could activate muscle proteolysis and found low values of both phosphatidylinositol 3 kinase (PI3K) activity and phosphorylated Akt that were related to phosphorylation of serine 307 of insulin receptor substrate-1. To assess how changes in circulating insulin and glucose affect muscle protein, we treated db/db mice with rosiglitazone. Rosiglitazone improved indices of insulin resistance and abnormalities in PI3K/Akt signaling and decreased activities of caspase-3 and the proteasome in muscle leading to suppression of proteolysis. Underlying mechanisms of proteolysis include increased glucocorticoid production, decreased circulating adiponectin, and phosphorylation of the forkhead transcription factor associated with increased expression of the E3 ubiquitin-conjugating enzymes atrogin-1/MAFbx and MuRF1. These abnormalities were also corrected by rosiglitazone. Thus, insulin resistance causes muscle wasting by mechanisms that involve suppression of PI3K/Akt signaling leading to activation of caspase-3 and the ubiquitin-proteasome proteolytic pathway causing muscle protein degradation.
This article has been cited by other articles:
![]() |
P. J. Plant, J. R. Bain, J. E. Correa, M. Woo, and J. Batt Absence of caspase-3 protects against denervation-induced skeletal muscle atrophy J Appl Physiol, July 1, 2009; 107(1): 224 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Q. Wang, Z. E. Floyd, J. Qin, X. Liu, Y. Yu, X. H. Zhang, J. D. Wagner, and W. T. Cefalu Modulation of Skeletal Muscle Insulin Signaling With Chronic Caloric Restriction in Cynomolgus Monkeys Diabetes, July 1, 2009; 58(7): 1488 - 1498. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Varma, A. Yao-Borengasser, N. Rasouli, G. T. Nolen, B. Phanavanh, T. Starks, C. Gurley, P. Simpson, R. E. McGehee Jr., P. A. Kern, et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1300 - E1310. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Crossland, D. Constantin-Teodosiu, S. M. Gardiner, D. Constantin, and P. L. Greenhaff A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle J. Physiol., November 15, 2008; 586(22): 5589 - 5600. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hu, J. D. Klein, J. Du, and X. H. Wang Cardiac Muscle Protein Catabolism in Diabetes Mellitus: Activation of the Ubiquitin-Proteasome System by Insulin Deficiency Endocrinology, November 1, 2008; 149(11): 5384 - 5390. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Bergen Measuring in vivo intracellular protein degradation rates in animal systems J Anim Sci, April 1, 2008; 86(14_suppl): E3 - E12. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. DeBoer, X. Zhu, P. R. Levasseur, A. Inui, Z. Hu, G. Han, W. E. Mitch, J. E. Taylor, H. A. Halem, J. Z. Dong, et al. Ghrelin Treatment of Chronic Kidney Disease: Improvements in Lean Body Mass and Cytokine Profile Endocrinology, February 1, 2008; 149(2): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhou, J. Du, Z. Hu, K. Walsh, and X. H. Wang Evidence for Adipose-Muscle Cross Talk: Opposing Regulation of Muscle Proteolysis by Adiponectin and Fatty Acids Endocrinology, December 1, 2007; 148(12): 5696 - 5705. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hu, I. H. Lee, X. Wang, H. Sheng, L. Zhang, J. Du, and W. E. Mitch PTEN Expression Contributes to the Regulation of Muscle Protein Degradation in Diabetes Diabetes, October 1, 2007; 56(10): 2449 - 2456. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Constantin, D. Constantin-Teodosiu, R. Layfield, K. Tsintzas, A. J. Bennett, and P. L. Greenhaff PPAR{delta} agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle J. Physiol., August 15, 2007; 583(1): 381 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Turner, C. R. Bruce, S. M. Beale, K. L. Hoehn, T. So, M. S. Rolph, and G. J. Cooney Excess Lipid Availability Increases Mitochondrial Fatty Acid Oxidative Capacity in Muscle: Evidence Against a Role for Reduced Fatty Acid Oxidation in Lipid-Induced Insulin Resistance in Rodents Diabetes, August 1, 2007; 56(8): 2085 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vermaelen, P. Sirvent, F. Raynaud, C. Astier, J. Mercier, A. Lacampagne, and O. Cazorla Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1723 - C1731. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |